• Not yet recruiting

NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)

Updated: Sep 30

(SUCCESSOR-2)

CC-92480 - Mezi - Mezigdomide - CELMoD


NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

CC-92480 + Carfilzomib-dex (480Kd)  Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)

NCT05552976: Phase 3: A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)


The purpose of the study is to compare CC-92480 (BMS-986348) with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM.


Sponsor

Bristol-Myers Squibb

 

ClinicalTrials.gov Identifier: NCT05552976

Official Title: A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted : September 23, 2022

Click here for details on ClinicalTrials.gov

 

cereblon E3 ubiquitin ligase modulating agent CC-92480

CC-92480


Mezigdomide (Code C146660)

CC 92480

CC-92480

CELMoD CC-92480

Cereblon E3 Ligase Modulation Drug CC-92480

Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480

Cereblon Modulator CC-92480

Mezigdomide

MEZIGDOMIDE

 

Drug: CC-92480

Drug: Carfilzomib

 

Locations

United States, Ohio

United States, South Carolina

Argentina

Australia, Queensland

Australia, Victoria

Australia

Europe

Asia

China, Beijing

China, Fujian

China, Guangdong

China, Hunan

China, Jiangsu

China, Jilin

China, Liaoning

China, Shaanxi

China, Shandong

China, Shanghai

China, Tianjin

China, Yunnan

China, Zhejiang

China

Colombia

Germany

Hong Kong

India

Singapore

Taiwan

 

RELATED POSTS

NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM

Click here for details


NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma

Click here for details


NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

Click here for details


NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma

Click here for details

CC-92480 MEZIGDOMIDE

Posts Archive